Loading…
Employees: 1,245
Size Shanghai Labway Clinical Laboratory (301060.SZ) is a China Health Care company (Medical/Nursing Services) with a market value of $593M, the 3451st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.87 on 6 Nov 2026.
Performance Over six months the shares fell 4.5%, against -1.1% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue fell 18.6% over the last twelve months (peer median +6.7%); the operating margin is 5.6% (peer median 8.0%).
Valuation It trades at 2.7× enterprise value to sales against a peer median of 1.4× (8th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points above its cost of capital (7.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.24B | CN¥1.45B | CN¥1.74B | CN¥1.67B | CN¥4.20B |
| Revenue growth | — | -17% | +4% | -60% | — |
| Gross profit | CN¥343M | CN¥308M | CN¥335M | CN¥317M | CN¥1.76B |
| EBITDA | n/a | CN¥117M | CN¥39.7M | -CN¥72.1M | CN¥1.17B |
| Net income | CN¥41.0M | -CN¥30.7M | -CN¥109M | -CN¥142M | CN¥617M |
| Free cash flow | CN¥300M | CN¥214M | CN¥140M | CN¥149M | -CN¥136M |
| Capital expenditure | CN¥47.9M | CN¥58.5M | CN¥76.6M | CN¥399M | CN¥230M |
| Total debt | CN¥99.9M | CN¥171M | CN¥274M | CN¥407M | CN¥350M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301060.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.7% | -4.5% | 6th lowest of 21 |
| 6-month return | -4.5% | -1.1% | 7th lowest of 19 |
| Distance from 52-week high | -32.2% | -24.5% | 10th lowest of 21 |
| Revenue growth (TTM) | -18.6% | +6.7% | 3rd lowest of 21 |
| Operating margin | 5.6% | 8.0% | 8th lowest of 21 |
| EV / Sales | 2.7× | 1.4× | 8th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 8.8% | 8.1% | 7th most demanding of 16 |
| Growth delivered (Del g) | +3.2% | +10.9% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | +5.5 pp | -9.9 pp | 5th most demanding of 16 |
| ROIC minus cost of capital | +3.4 pp | -2.2 pp | 6th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | 2.7× | 8.8% | +3.2% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 5.8× | 35.7% | +31.6% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | 1.2× | n/a | n/a |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 0.9× | -20.0% | -4.0% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 1.6× | n/a | n/a |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | 28.2× | n/a | n/a |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 0.9× | -10.8% | +12.2% |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 1.4× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | 7.7× | n/a | n/a |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 1.5× | 8.3% | +17.7% |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 2.9× | 18.0% | +12.4% |
| Jeena Sikho Lifecare JSLL.NS | India | $424M | -56% | +162% | 36% | 4.7× | 8.1% | +42.6% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 8.3× | 27.9% | +10.9% |
| Australian Clinical Labs ACL.AX | Australia | $419M | +74% | -1% | 8% | 1.3× | 3.9% | +2.6% |
| ADICON 9860.HK | Hong Kong | $408M | +9% | +1% | 4% | 1.3× | 12.0% | -1.5% |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 1.2× | -4.6% | +5.3% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 0.6× | -9.7% | +1.6% |
| Tellgen 300642.SZ | China | $387M | -3% | +5% | 8% | 6.2× | 22.4% | -5.8% |
| M1 Kliniken M12.DE | Germany | $376M | +3% | -28% | 13% | 1.2× | -5.5% | +17.9% |
| Oncology Institute STLN | United States | $362M | n/a | +38% | -4% | 0.7× | n/a | n/a |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $353M | +6% | 0% | -2% | 0.4× | -15.1% | +9.6% |